Vipivotide tetraxetan (also known as PSMA-617) is a radiopharmaceutical precursor molecule used in targeted therapies for prostate cancer and other tumors expressing prostate-specific membrane antigen (PSMA).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.